

## Product Data Sheet

Product Name: NEO-811

Cat. No.: GC81031

### Chemical Properties

Cas. No. 3084635-77-5

Formula  $C_{30}H_{30}FN_5O_4$

M.Wt 543.59


Solubility

Storage Store at -20°C

General tips For obtaining a higher solubility, please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution: ship with blue ice. All other available size: ship with RT, or blue ice upon request.

Structure



### Background

NEO-811 is a selective and orally active ARNT (HIF-1 $\beta$ ) molecular glue degrader. NEO-811 is mediated by CRL4-CRBN E3 ligase for ARNT degradation. NEO-811 can be used for the study of clear cell renal cell carcinoma (ccRCC) [1] [2].

In Vitro, NEO-811 is highly selective and does not degrade well-known neosubstrates. Transcriptomic profiling of NEO-811 activity across several VHL-deficient ccRCC cell lines confirmed suppression of HIF-2 $\alpha$  target genes, including cyclin D and vascular endothelial growth factor (VEGF). NEO-811 also uniquely suppresses expression of target genes regulated by other Class I

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

## Product Data Sheet

---

bHLH-PAS transcription factors, including HIF-1 $\alpha$  and aryl hydrocarbon receptor (AHR). NEO-811 retains activity in HIF-2 $\alpha$  inhibitor-resistant cells that harbored previously described mutations<sup>[2]</sup>.

### References:

- [1]. Jennifer Griffin, et al. Abstract 6734: Discovery and optimization of NEO-811, a first-in-class molecular glue degrader of ARNT, utilizing structure-based drug design. Cancer Res (2026) 86 (7\_Supplement): 6734.
- [2]. J. Scott Lee, et al. Abstract 5791: Preclinical characterization of NEO-811, a novel molecular glue degrader of ARNT for the treatment of clear cell renal cell carcinoma. Cancer Res (2026) 86 (7\_Supplement): 5791.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: [tech@glpbio.com](mailto:tech@glpbio.com)

Address: 10292 Central Ave. #205, Montclair, CA, USA